```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  JAN 08   CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS  3  JAN 16   CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS  4  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS  5  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS  6  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS  7  JAN 22   CA/CAplus enhanced with patent applications from India
 NEWS  8  JAN 29   PHAR reloaded with new search and display fields
 NEWS  9  JAN 29   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases
 NEWS 10  FEB 15   PATDPASPC enhanced with Drug Approval numbers
 NEWS 11  FEB 15   RUSSIAPAT enhanced with pre-1994 records
 NEWS 12  FEB 23   KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 13  FEB 26   MEDLINE reloaded with enhancements
 NEWS 14  FEB 26   EMBASE enhanced with Clinical Trial Number field
 NEWS 15  FEB 26   TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16  FEB 26   IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17  FEB 26   CAS Registry Number crossover limit increased from 10,000
                   to 300,000 in multiple databases
 NEWS 18  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS 19  MAR 16   CASREACT coverage extended
 NEWS 20  MAR 20   MARPAT now updated daily
 NEWS 21  MAR 22   LWPI reloaded
 NEWS 22  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS 23  MAR 30   INPADOCDB will replace INPADOC on STN
 NEWS 24  APR 02   JICST-EPLUS removed from database clusters and STN

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:23:01 ON 26 APR 2007

=> file reg
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:23:32 ON 26 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 APR 2007 HIGHEST RN 932710-95-7
DICTIONARY FILE UPDATES: 25 APR 2007 HIGHEST RN 932710-95-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10530571.str



chain nodes :
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11

```
chain bonds :
8-14  8-15  9-12  9-13  10-16  11-17  17-18  17-26  18-19  18-25  19-20  19-27
20-21  20-24  21-22  21-23
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-11  7-8  8-9  9-10  10-11
exact bonds :
5-7  6-11  7-8  8-9  8-14  8-15  9-10  9-12  9-13  10-11  10-16  11-17  17-18
17-26  18-19  18-25  19-20  19-27  20-21  20-24
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  21-22  21-23
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS
27:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 13:24:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        7 TO ITERATE

100.0% PROCESSED        7 ITERATIONS                                 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            7 TO      298
PROJECTED ANSWERS:               3 TO      163

L2            3 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:26:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       65 TO ITERATE

100.0% PROCESSED       65 ITERATIONS                                26 ANSWERS
SEARCH TIME: 00.00.01

L3           26 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               173.90     174.11

FILE 'CAPLUS' ENTERED AT 13:26:37 ON 26 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

FILE COVERS 1907 - 26 Apr 2007 VOL 146 ISS 18
FILE LAST UPDATED: 25 Apr 2007 (20070425/ED)

=> s l3 full
L4 7 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1328491 CAPLUS
DOCUMENT NUMBER: 146:190124
TITLE: Bioavailability enhancement of an active substance by supercritical antisolvent precipitation
AUTHOR(S): Majerik, Viktor; Charbit, Gerard; Badens, Elisabeth; Horvath, Geza; Szokonya, Laszlo; Bosc, Nathalie; Teillaud, Eric
CORPORATE SOURCE: Department of Chemical Engineering, Pannon University, Veszprem, H-8201, Hung.
SOURCE: Journal of Supercritical Fluids (2007), 40(1), 101-110
CODEN: JSFLEH; ISSN: 0896-8446
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Oxeglitazar is a new orally administered poorly water soluble active substance used in the treatment of type II diabetes. Our research aimed to improve the bioavailability of this active substance using Supercrit. Antisolvent (SAS) process. Oxeglitazar was copptd. with various solubilizing excipients: polyoxyethylene-polyoxypropylene block copolymers (Poloxamer 188 and 407), polyethylene glycol (PEG 8000) and polyvinilpyrrolidone (PVP K17) from six different solvents: Ethanol (EtOH), THF, dichloromethane (DCM), chloroform (CHCl3), N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO) and two binary solvent mixts.: EtOH/THF (50:50%, volume/volume) and EtOH/CHCl3 (50:50%, volume/volume). Formulations were compared in terms of particle morphol., crystallinity, polymorphic purity, residual solvent content, precipitation yield and dissoln. kinetics. SAS formulations of oxeglitazar-PEG 8000, Poloxamer 188 and 407 contained acicular drug crystals that were partly embedded in polymeric spheres while expts. with PVP K17 resulted in quasi amorphous solid dispersions with high d. and good flowability. In spite of the greater particle size, SAS formulations exhibited significantly greater dissoln. rate compared to raw drug and phys. mixts. More than twice as much active substance was dissolved at 5 min from Poloxamer 407 and PVP K17 formulations than from unprocessed drug. In addition, SAS prepared Poloxamer 407 formulation from DCM solution exhibited high polymorphic purity, good flow properties, acceptable precipitation yield and low residual solvent content.

IT 280585-34-4, Oxeglitazar
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioavailability enhancement of an active substance by supercrit. antisolvent precipitation)
RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1253003 CAPLUS
DOCUMENT NUMBER: 146:804
TITLE: insulin sensitization for delaying puberty and increasing growth
INVENTOR(S): De Zegher, Francis; Dunger, David; Ibanez, Lourdes
PATENT ASSIGNEE(S): K.U. Leuven Research and Development, Belg.; Addenbrooke's Hospital
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125285	A1	20061130	WO 2006-BE60	20060523
WO 2006125285	B1	20070111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2005-10469 A 20050523
OTHER SOURCE(S): MARPAT 146:804

AB In accordance with the purpose of the invention, as embodied and broadly described herein, the invention is broadly drawn to a new method of treatment, the use of agents to manufacture a composition of treatment or the composition of treatment for the prevention of rapidly progressive puberty, the prevention of early menarche or the modulation, more particularly the delay, of the tempo of puberty in a female mammal, preferably a human

girl, and the disorders related thereto. In a particular embodiment the present invention involves the use of at least one insulin-sensitizing agent such as metformin, any of the polymorphs of metformin or a pharmaceutically acceptable salt thereof for the preparation of a composition of
treatment to modulate the tempo of pubertal progression in a girl. Metformin administration to girls experiencing precocious puberty resulted in normalization of pubertal progression to menarche, increased height gains, leaner body composition, and decreases indexes relating to insulin resistance.

IT 280585-34-4, Oxeglitazar
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metformin-induced insulin sensitization for delaying puberty and increasing growth)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1345487 CAPLUS
DOCUMENT NUMBER: 144:69749
TITLE: Preparation of 3,3-dimethylbenzoxepin-5-ylalkenones as intermediates for antidiabetic pentadienoic acids
INVENTOR(S): Brunet, Michel; Le Borgne, Guy
PATENT ASSIGNEE(S): Merck Sante, Fr.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1609786	A1	20051228	EP 2004-291616	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
WO 2006002721	A1	20060112	WO 2005-EP5693	20050527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,				

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1758876 A1 20070307 EP 2005-747039 20050527

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV

PRIORITY APPLN. INFO.: EP 2004-291616 A 20040625

WO 2005-EP5693 W 20050527

OTHER SOURCE(S): CASREACT 144:69749; MARPAT 144:69749

GI



I

AB Title compds. [I; R = H, (substituted) alkyl, aryl; R1 = halo, cyano, NO2, CO2H, (halo)alkoxycarbonyl, etc.; p = 0-4], were prepared Thus, 3,3-dimethyl-7-ethyl-2,3,4,5-tetrahydrobenzoxazepin-5-one, triflic anhydride, and pyridine were refluxed together in CH2Cl2 for 4 h to give 100% 3,3-dimethyl-5-trifluoromethanesulfonyloxy-7-ethyl-2,3-dihydroobenzoxazepine. The latter was heated with Me vinyl ketone, (PPh3)2PdCl2, and Et3N in DMF at 70-75° for 5 h to give 96% (3E)-4-(3,3-dimethyl-7-ethyl-2,3-dihydrobenzoxepin-5-yl)buten-2-one.

IT 280585-64-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of dimethylbenzoxepinylalkenones as intermediates for antidiabetic pentadienoic acids)

RN 280585-64-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-ethyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:523273 CAPLUS
DOCUMENT NUMBER: 143:53517
TITLE: Use of pentadienoic acid derivatives for the treatment of hyperuricemia
INVENTOR(S): Boizel, Robert; Fouqueray, Pascale; Guerrier, Daniel; Zeiller, Jean-Jacques; Brutzkus, Bertrand
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053676	A1	20050616	WO 2004-EP12381	20041102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1535612	A1	20050601	EP 2003-292973	20031128
EP 1535612	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004294686	A1	20050616	AU 2004-294686	20041102
CA 2547543	A1	20050616	CA 2004-2547543	20041102
EP 1686983	A1	20060809	EP 2004-797525	20041102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1886129	A	20061227	CN 2004-80035212	20041102
BR 2004017003	A	20070116	BR 2004-17003	20041102

PRIORITY APPLN. INFO.:	EP 2003-292973	A	20031128
	US 2003-527773P	P	20031209
	WO 2004-EP12381	W	20041102

OTHER SOURCE(S): MARPAT 143:53517
GI



I

AB The use of a pentadienoic acid derivative of formula I (e.g., (2E,4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta -2,4-dienoic acid) is claimed for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compns. for these prevention and/or treatment, comprising such a pentadienoic acid derivative
IT 280585-34-4, (2E,4E)-5-(2,3-Dihydro-3,3-Dimethyl-7-methoxy-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-39-9, (2Z,4E)-5-(3,3-Dimethyl-7-methoxy-2,3-dihydro-1-benzoxepin-5-yl)-3-

methylpenta-2,4-dienoic acid 280585-41-3, (2E,4E)-5-(3,3-Dimethyl-7,8-dimethoxy-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-43-5, (2E,4E)-5-(3,3-Dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-45-7, (2E,4E)-5-[3,3-Dimethyl-2,3-dihydro-7-(para-chlorobenzoyl)-1-benzoxepin-5-yl]-3-methylpenta-2,4-dienoic acid 280585-47-9, (2E,4E)-5-(3,3-Dimethyl-7-chloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-48-0, (2E,4E)-5-(3,3-Dimethyl-7,8-dichloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-50-4, (2E,4E)-5-(3,3-Dimethyl-7-bromo-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-51-5, (2E,4E)-5-(3,3-Dimethyl-7-fluoro-8-chloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-53-7, (2E,4E)-5-(3,3-Dimethyl-7-fluoro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-55-9, (2E,4E)-5-(3,3-Dimethyl-7-trifluoromethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-57-1, (2E,4E)-5-(3,3-Dimethyl-7-phenyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280586-03-0, (2E,4E)-5-(3,3,7-Trimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 852550-63-1, (2E,4E)-5-(9-Methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of pentadienoic acid derivs. for treatment of hyperuricemia)

RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-39-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-41-3 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-43-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-45-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-47-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-48-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-50-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-51-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-53-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-

yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-55-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-57-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280586-03-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 852550-63-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-9-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:467780 CAPLUS
DOCUMENT NUMBER: 143:1300
TITLE: Use of pentadienoic acid derivatives for the prevention and/or the treatment of hyperuricemia
INVENTOR(S): Boizel, Robert; Fouqueray, Pascale; Guerrier, Daniel; Zeller, Jean-Jacques; Brutzkus, Bertrand
PATENT ASSIGNEE(S): Merck Sante, Fr.
SOURCE: Eur. Pat. Appl., 45 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1535612	A1	20050601	EP 2003-292973	20031128
EP 1535612	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 339200	T	20061015	AT 2003-292973	20031128
AU 2004294686	A1	20050616	AU 2004-294686	20041102
CA 2547543	A1	20050616	CA 2004-2547543	20041102
WO 2005053676	A1	20050616	WO 2004-EP12381	20041102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1686983	A1	20060809	EP 2004-797525		20041102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1886129	A	20061227	CN 2004-80035212		20041102
BR 2004017003	A	20070116	BR 2004-17003		20041102
PRIORITY APPLN. INFO.:			EP 2003-292973	A	20031128
			US 2003-527773P	P	20031209
			WO 2004-EP12381	W	20041102

OTHER SOURCE(S): MARPAT 143:1300

AB Use of pentadienoic acid derivs. for the prevention and/or the treatment of hyperuricemia and/or associated disorders or diseases. The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compns. for these prevention and/or treatment, comprising such a pentadienoic acid derivative

IT 280585-34-4 280585-39-9 280585-41-3
280585-43-5 280585-45-7 280585-47-9
280585-48-0 280585-50-4 280585-51-5
280585-53-7 280585-55-9 280585-57-1
280586-03-0 852550-63-1
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of pentadienoic acid derivs. for prevention and the treatment of hyperuricemia)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-39-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-41-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-43-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-45-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-47-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-48-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-50-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-51-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-53-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-

yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-55-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-57-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280586-03-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 852550-63-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-9-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:291092 CAPLUS
DOCUMENT NUMBER: 140:303553
TITLE: New metastable benzoxepine derivatives used for treating dyslipidemia, atherosclerosis, and diabetes, pharmaceutical compositions containing them, and their preparation processes by salt formation and acidulation
INVENTOR(S): Bosc, Nathalie; Festal, Didier; Boudet, Bernard
PATENT ASSIGNEE(S): Merck Sante, Fr.
SOURCE: Fr. Demande, 29 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2845386	A1	20040409	FR 2002-12432	20021007
FR 2845386	B1	20060630		
CA 2502877	A1	20040415	CA 2003-2502877	20030901
WO 2004031166	A1	20040415	WO 2003-EP9680	20030901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003264139	A1	20040423	AU 2003-264139		20030901
EP 1549630	A1	20050706	EP 2003-798880		20030901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006503073	T	20060126	JP 2004-540566		20030901
US 2006041007	A1	20060223	US 2005-530571		20050407
PRIORITY APPLN. INFO.:			FR 2002-12432	A	20021007
			WO 2003-EP9680	W	20030901

OTHER SOURCE(S): MARPAT 140:303553

GI



I

AB The invention is directed to the preparation of new metastable benzoxepines I by salt formation of I and precipitation of I by acidulation of the aqueous salt solution, and their use for treating dyslipidemia, atherosclerosis, and diabetes [n = 0, 1, or 2; R = independently alkyl, alkoxy, halo]. Thus, addition of aqueous NaOH solution to the stable form of I (R = OMe) (II), followed by acidulation with aqueous H2SO4 afforded the metastable form of II in 99% yield (m.p. = 151-153° by DTA). The metastable form has a higher sp. surface area than the stable form, while their densities are comparable.

IT 280585-34-4P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(intermediate stable form, metastable product; preparation of metastable benzoxepines by salt formation and acidulation for treating dyslipidemia, atherosclerosis, and diabetes)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:457054 CAPLUS
DOCUMENT NUMBER: 133:89445
TITLE: Preparation of benzopyrans and benzoxepines and their hypolipidemic and antidiabetic activity
INVENTOR(S): Brunet, Michel; Zeiller, Jean Jaques; Berthelon, Jean Jaques; Contard, Francis; Augert, Guy; Guerrier, Daniel
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039113	A1	20000706	WO 1999-EP10114	19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2787789	A1	20000630	FR 1998-16574	19981229
FR 2787789	B1	20020614		
CA 2356680	A1	20000706	CA 1999-2356680	19991220
BR 9916633	A	20010925	BR 1999-16633	19991220
EP 1140893	A1	20011010	EP 1999-967960	19991220
EP 1140893	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 200104839	A2	20020429	HU 2001-4839	19991220
AU 759892	B2	20030501	AU 2000-24329	19991220
JP 2003517449	T	20030527	JP 2000-591024	19991220
RU 2228333	C2	20040510	RU 2001-120380	19991220
CN 1554651	A	20041215	CN 2004-10047645	19991220
NO 2001003242	A	20010628	NO 2001-3242	20010628
US 6596758	B1	20030722	US 2001-869518	20010629
ZA 2001006177	A	20021028	ZA 2001-6177	20010726
HK 1047584	A1	20050527	HK 2002-108653	20021129

PRIORITY APPLN. INFO.: FR 1998-16574 A 19981229
WO 1999-EP10114 W 19991220

OTHER SOURCE(S): MARPAT 133:89445
GI



I

AB The title compds. I [X = O, S; A = (CH2)sCO(CH2)t, (CH2)sCR3R4(CH2)t and s = t = 0, or one of s and t is 0 and the other is 1; R1, R2 = H, alkyl, alkenyl, alkynyl, etc.; R = halo, cyano, NO2, etc.] were prepared E.g., (2E,4E)-5-(2-pentyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid was prepared The hypolipidemic and antidiabetic activity of I were

investigated.

IT 280585-34-4P 280585-39-9P 280585-41-3P
280585-43-5P 280585-45-7P 280585-47-9P
280585-48-0P 280585-50-4P 280585-51-5P
280585-53-7P 280585-55-9P 280585-57-1P
280585-60-6P 280585-64-0P 280585-66-2P
280585-68-4P 280585-70-8P 280585-72-0P
280585-74-2P 280585-77-5P 280585-81-1P
280585-83-3P 280585-93-5P 280586-01-8P
280586-03-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzopyrans and benzoxepines and their hypolipidemic and antidiabetic activity)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-39-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-41-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-43-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-45-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-47-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-48-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-50-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-51-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-53-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-55-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-

benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-57-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-60-6 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-6-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-64-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-ethyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-66-2 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-7-(4-methoxyphenyl)-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-68-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7,8-tetramethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-70-8 CAPLUS
CN 2,4-Pentadienoic acid, 5-[8-(4-fluorophenyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-72-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-8-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-74-2 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(1-methylethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-77-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethoxy)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-81-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-hydroxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-83-3 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-[4-(trifluoromethyl)phenyl]-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-93-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-cyclohexyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280586-01-8 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-ethoxy-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280586-03-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:23:01 ON 26 APR 2007)

FILE 'REGISTRY' ENTERED AT 13:23:32 ON 26 APR 2007
L1 STRUCTURE UPLOADED
L2 3 S L1
L3 26 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:26:37 ON 26 APR 2007

```
L4             7 S L3 FULL

=> d his

     (FILE 'HOME' ENTERED AT 13:23:01 ON 26 APR 2007)

     FILE 'REGISTRY' ENTERED AT 13:23:32 ON 26 APR 2007
L1               STRUCTURE UPLOADED
L2             3 S L1
L3            26 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 13:26:37 ON 26 APR 2007
L4             7 S L3 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    39.71     213.82

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.46      -5.46

STN INTERNATIONAL LOGOFF AT 13:30:06 ON 26 APR 2007
```